Mild Cognitive Impairment: Clinical Trials

139 trials for Mild Cognitive Impairment, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

80 completed, 19 unknown, 16 recruiting, 9 active not recruiting. 139 Phase 2, 23 Phase 1, 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2139Completed 80, Unknown 19, Recruiting 16, Active not recruiting 9, Terminated 7, Not yet recruiting 4, Withdrawn 4
Phase 123Completed 12, Unknown 5, Recruiting 3, Not yet recruiting 2, Active not recruiting 1
Phase 39Completed 5, Active not recruiting 2, Unknown 2

Follow Mild Cognitive Impairment: new trials by email Literature Review of Mild Cognitive Impairment trials Research Report on Mild Cognitive Impairment

Trials (filtered) newest first · largest first

All 139 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
2-hydroxybenzylamine acetate, Placebo - Alzheimer Disease, Mild Cognitive Impairment
Phase 1 / Phase 2Not yet recruitingMTI Biotech Inc482026-09-012026-09-24
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
human Mesenchymal Stem Cells - Mild Cognitive Impairment, Early Alzheimer's Disease
Phase 2RecruitingBernard (Barry) Baumel102026-05-152026-05-28
Sense4Safety Intervention
Sense4Safety - Mild Cognitive Impairment
Phase 1 / Phase 2RecruitingUniversity of Pennsylvania2002026-02-192026-03-19
Glymphatic Function TMS Study
Transcranial Magnetic Stimulation - Mild Cognitive Impairment
Phase 2Not yet recruitingUniversity of Arizona202026-01-012025-12-17
Epileptic Hippocampus in Alzheimer's Disease
Brivaracetam - Alzheimer Disease, Mild Cognitive Impairment
Phase 1 / Phase 2Not yet recruitingUniversity of California, Los Angeles252026-01-012026-01-27
The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment
Metfomin - Mild Cognitive Impairment, Overweight or Obesity
Phase 1 / Phase 2RecruitingFudan University542025-09-012026-02-09
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
18F-Florbetapir or 18F-Flutemetamol - Alzheimer Disease, Mild Cognitive Impairment
Phase 2RecruitingAkiva Mintz2002025-05-202026-04-13
SNIFF - 3-Week Aptar CPS Device
Insulin (Humulin® R U-100), Placebo, Aptar Pharma CPS Intranasal Delivery Device - Mild Cognitive Impairment, Cognitive Impairment
Phase 2WithdrawnWake Forest University Health Sciences2025-05-012025-07-28
A Study of NTRX-07 in Participants With Alzheimer's Disease
NTRX-07, Placebo - Alzheimer Disease, Mild Cognitive Impairment
Phase 2CompletedNeuroTherapia, Inc.482025-03-012026-10-29
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
Sublingual administration, Electroencephalography, Biochemical mesurements - Mild Cognitive Impairment, Anxiety State
Phase 1 / Phase 2CompletedBiomind Labs Inc.202024-12-152025-04-09
Clinical Trial of AGB101 for Mild Cognitive Impairment
AGB101, Placebo - Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Phase 2WithdrawnAgeneBio2024-12-032025-05-25
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
IV Ketamine - Depression, Mild Cognitive Impairment
Phase 2Active not recruitingIcahn School of Medicine at Mount Sinai152024-11-012025-01-29
A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)
Lamivudine 300 MG - Mild Cognitive Impairment
Phase 2Active not recruitingFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia232024-10-282025-12-04
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Mitoquinone Mesylate, Placebo capsule - Frailty, Mild Cognitive Impairment
Phase 2RecruitingUConn Health602024-10-072026-08-12
tDCS for Post-Stroke Cognitive Impairment
Transcranial Dirrect Current Stimulation - Stroke, Mild Cognitive Impairment
Phase 2RecruitingUniversity of Oklahoma802024-09-302024-10-10
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
Ginkgo biloba extract 50 dropping pills, Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant - Mild Cognitive Impairment
Phase 2 / Phase 3Active not recruitingBeijing Tiantan Hospital1442024-09-272026-10-08
RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β
Resveratrol, Quercetin, and Curcumin (RQC), Curcumin - Alzheimer Disease, Mild Cognitive Impairment
Phase 2Not yet recruitingZaparackas and Knepper LTD2002024-07-012024-06-26
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
DAOIB plus AO, DAOIB plus placebo - Alzheimer Disease, Mild Cognitive Impairment
Phase 2RecruitingChang Gung Memorial Hospital802024-06-192026-03-19
COMMETS- Combination MCI Metabolic Syndrome
Semaglutide, Intranasal insulin, Semaglutide placebo - Alzheimer Disease, Mild Cognitive Impairment
Phase 2RecruitingRutgers, The State University of New Jersey802024-01-302026-07-27
CBD for Individuals at Risk for Alzheimer's Disease
Cannabidiol, Placebo - Mild Cognitive Impairment
Phase 2RecruitingUniversity of Colorado, Denver2362024-01-192026-06-15

Showing 20 of 139. Sign in to see all of them.

Narrower conditions

Cognitive Dysfunction (139)  ·  Alzheimer Disease (74)  ·  Dementia (17)  ·  Memory Disorders (9)  ·  Neurodegenerative Diseases (6)  ·  Parkinson Disease (6)  ·  Cognition Disorders (5)  ·  Tauopathies (5)  ·  Brain Diseases (4)  ·  Central Nervous System Diseases (4)  ·  Inflammation (4)  ·  Neurocognitive Disorders (4)  ·  Depression (3)  ·  Insulin Resistance (3)  ·  Metabolic Syndrome (3)

Broader conditions

Mental Disorders (137)  ·  Neurocognitive Disorders (135)  ·  Cognition Disorders (134)  ·  Nervous System Diseases (87)  ·  Brain Diseases (85)  ·  Central Nervous System Diseases (85)  ·  Neurodegenerative Diseases (73)  ·  Tauopathies (69)  ·  Dementia (64)  ·  Pathological Conditions, Signs and Symptoms (22)  ·  Signs and Symptoms (14)  ·  Neurologic Manifestations (12)  ·  Neurobehavioral Manifestations (11)  ·  Nutritional and Metabolic Diseases (10)  ·  Metabolic Diseases (9)

Interventions

Insulin (6)  ·  florbetapir (5)  ·  Levetiracetam (3)  ·  Quercetin (3)  ·  Sodium Chloride (3)  ·  Transcranial Direct Current Stimulation (3)  ·  Atorvastatin (2)  ·  Curcumin (2)  ·  Dasatinib (2)  ·  Donepezil (2)  ·  Insulin Detemir (2)  ·  Memantine (2)  ·  Metformin (2)  ·  Tablets (2)  ·  Tobacco Use Cessation Devices (2)

Sponsors

Wake Forest University Health Sciences (5)  ·  Avid Radiopharmaceuticals (4)  ·  Chang Gung Memorial Hospital (4)  ·  University of Washington (4)  ·  Emory University (3)  ·  Massachusetts General Hospital (3)  ·  AgeneBio (2)  ·  Beijing Tiantan Hospital (2)  ·  Columbia University (2)  ·  Jae Seung Kim (2)  ·  Johns Hopkins University (2)  ·  New York State Psychiatric Institute (2)  ·  Sutter Health (2)  ·  The University of Texas Health Science Center at San Antonio (2)  ·  University of Arizona (2)

Countries

United States (84)  ·  Netherlands (6)  ·  Australia (5)  ·  France (5)  ·  Spain (5)  ·  Taiwan (5)  ·  Canada (4)  ·  China (4)  ·  Germany (4)  ·  United Kingdom (4)  ·  Czechia (3)  ·  Ireland (3)  ·  Singapore (3)  ·  Sweden (3)  ·  Finland (2)

Top investigators

Suzanne Craft, PhD (8)  ·  Philip Scheltens, MD (2)  ·  Adrian S Wagg, MD (1)  ·  Agnes Floeel, Prof. (1)  ·  Alexander C Conley, PhD (1)  ·  Allan I. Levey, MD, PhD (1)  ·  Andreana Haley, Ph.D. (1)  ·  Arjan Blokland, Prof. Dr. (1)  ·  Ashley I. Bush (1)  ·  Barry Halliwell (1)  ·  Barry Rovner, MD (1)  ·  Bernard S. Baumel, MD (1)  ·  Brian D Ross (1)  ·  Bruno Vellas, MD (1)

Results publications

PMID 34366147, PMID 20204386, PMID 20664181, PMID 21911655, PMID 22869065, PMID 23040716, PMID 23528880, PMID 23689947, PMID 24716655, PMID 25589719, PMID 26420886, PMID 26433119, PMID 26559790, PMID 26890736, PMID 26912492, PMID 26967219, PMID 27037094, PMID 27511061, PMID 27871675, PMID 28095900, PMID 28181118, PMID 28326010, PMID 28950419, PMID 29016744, PMID 29336496, PMID 29371333, PMID 29379114, PMID 29446769, PMID 29573529, PMID 31236801, PMID 31248555, PMID 31424410, PMID 31492718, PMID 31518224, PMID 31535829, PMID 31810978, PMID 31834916, PMID 32115470, PMID 32116309, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32761160, PMID 32854852, PMID 32980252, PMID 33030307, PMID 33189083, PMID 33282811

NIH funding

2018 (2), 2016 (1), 2017 (1), 2019 (1), IK2RX002938 (1), K01AG054731 (1), K01AG080164 (1), P30AG024978 (1), P50AG005136 (1), R01AG025502 (1), R01AG025515 (1), R01AG025525 (1), R01AG026413 (1), R01AG027415 (1), R01AG028746 (1)